Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00531778 · ClinicalTrials.gov registry record
NYU Ovarian Cancer Early Detection Program Blood and Genetics
A clinical trial, sponsored by NYU Langone Health.
- Terminated
- Registry status
- 890
- Enrollment target
NCT00531778: Clinical Trial study, sponsored by NYU Langone Health.
NCT00531778 is a clinical trial that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 890 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00531778 was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- 890 participants
- Enrollment target
Study Summary
Improving current strategies for detection of early stage disease can impact favorably on long-term survival of women with ovarian cancer. To reduce the morbidity and mortality of ovarian cancer, screening for this disease must detect early stage disease rather than advanced stage disease. Thus the challenge for the future is to identify and develop highly sensitive and specific tumor markers that can be applied to population-based screening for the early detection of ovarian cancer.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 890 participants |
| Start Date | 2004-06 |
| Est. Completion | 2010-11 |
Why NCT00531778 stopped before completion
NCT00531778 is an observational study that tracks outcomes without assigning an intervention. The registered 890 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00531778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00531778 about?
NCT00531778 is a clinical study titled "NYU Ovarian Cancer Early Detection Program Blood and Genetics". Improving current strategies for detection of early stage disease can impact favorably on long-term survival of women with ovarian cancer. To reduce the morbidity and mortality of ovarian cancer, screening for this disease must detect early stage disease rather than advanced stage disease. Thus the ...
What is the current status of trial NCT00531778?
This trial is currently terminated. The enrollment target is 890 participants. The study started on 2004-06. Estimated completion is 2010-11.
Who is sponsoring clinical trial NCT00531778?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT05855200 · 892 participants · Phase 3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT07196748 · 882 participants · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia